Production (Stage)
VYNE Therapeutics Inc.
VYNE
$1.04
$0.044.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.11% | -40.00% | -5.56% | 18.97% | 13.20% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -54.58% | -71.85% | -70.55% | -58.18% | -48.00% |
| Change in Net Operating Assets | 412.25% | 8,233.33% | -19.87% | -103.14% | -136.29% |
| Cash from Operations | -34.50% | -34.06% | -20.36% | 0.88% | -8.60% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 171.12% | 140.94% | -1,134.33% | -1,054.28% | -1,441.26% |
| Cash from Investing | 170.94% | 140.74% | -1,134.33% | -1,054.28% | -1,441.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 52,890.38% | 52,890.38% | 52,890.38% |
| Repurchase of Common Stock | -279.66% | -111.94% | 82.35% | -21.28% | 53.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | 100.00% | 100.00% | 100.00% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.27% | -100.17% | 135,596.72% | 206,620.00% | 86,147.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 181.44% | -3,470.76% | 104.07% | 140.49% | 46.39% |